Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)

Open Forum Infectious Diseases

Volumn 7, Issue 4, 2020, Pages

  Pastick, Katelyn A ^a   Okafor, Elizabeth C ^a   Wang, Fan ^b   Lofgren, Sarah M ^a   Skipper, Caleb P ^a   Nicol, Melanie R ^b   Pullen, Matthew F ^a   Rajasingham, Radha ^a   McDonald, Emily G ^c   Lee, Todd C ^c   Schwartz, Ilan S ^d   Kelly, Lauren E ^e   Lother, Sylvain A ^e   Mitjà, Oriol ^f   Letang, Emili ^g,h   Abassi, Mahsa ^a   Boulware, David R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

chloroquine; clinical trials; coronavirus; SARS CoV 2. ; COVID 19; Hydroxychloroquine

Indexed keywords

AZITHROMYCIN; CHLOROQUINE; HYDROXYCHLOROQUINE; LOPINAVIR PLUS RITONAVIR;

ARTIFICIAL VENTILATION; CORONAVIRUS DISEASE 2019; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SAFETY; EC50; GENE SEQUENCE; HEALTH CARE QUALITY; HEART ARRHYTHMIA; HUMAN; IMMUNOFLUORESCENCE TEST; MALARIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRAL CLEARANCE; VIRUS REPLICATION;

EID: 85083885814     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofaa130     Document Type: Review

References (56)

1. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report - 75. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200401-sitrep-72-covid-19.pdf?sfvrsn=3dd8971b_2. Accessed 4 April 2020.
2. NIH U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/. Accessed 4 April 2020.
3. Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med 2020; In Press.
4. Tönnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy - a review of the literature. Immunopharmacol Immunotoxicol 2013; 35:434–42.
5. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42:145–53.
6. Concordia Pharmaceuticals Inc. Plaquenil Hydroxychloroquine Sulfate Tablets, USP; 2017.
7. Sanofi-Aventis US. LLC. Aralen Chloroquine Phosphate, USP; 2013.
8. Koranda FC. Antimalarials. J Am Acad Dermatol 1981; 4:650–5.
9. Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol 2011; 23:278–81.
10. De Carolis S, Botta A, Salvi S, et al. Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? Autoimmun Rev 2015; 14:760–2.
11. Belizna CC, Richard V, Thuillez C, et al. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev 2007; 7:46–51.
12. Savarino A, Shytaj IL. Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. Retrovirology 2015; 12:51.
13. Rebecca VW, Amaravadi RK. Emerging strategies to effectively target autophagy in cancer. Oncogene 2016; 35:1–11.
14. Drent M, Proesmans VLJ, Elfferich MDP, et al. Ranking self-reported gastrointestinal side effects of pharmacotherapy in sarcoidosis. Lung 2020; 198:395–403.
15. Srinivasa A, Tosounidou S, Gordon C. Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue? J Rheumatol 2017; 44:398.
16. Tétu P, Hamelin A, Lebrun-Vignes B, et al. [Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: a retrospective survey of 102 patients]. Ann Dermatol Venereol 2018; 145:395–404.
17. Arnaout A, Robertson SJ, Pond GR, et al. A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients. Breast Cancer Res Treat 2019; 178:327–35.
18. Global Health, Division of Parasitic Diseases and Malaria. Choosing a drug to prevent malaria. 2020. Available at: https://www.cdc.gov/malaria/travelers/drugs.html. Accessed 6 April 2010.
19. Jorge A, Ung C, Young LH, et al. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. Nat Rev Rheumatol 2018; 14:693–703.
20. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 1996; 31:257–74.
21. Furst DE, Lindsley H, Baethge B, et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 1999; 42:357–65.
22. Kobak S, Deveci H. Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. Int J Rheum Dis 2010; 13:e11–5.
23. Marmor MF, Kellner U, Lai TY, et al.; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 2016; 123:1386–94.
24. Mzayek F, Deng H, Mather FJ, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007; 2:e6.
25. O’Laughlin JP, Mehta PH, Wong BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep Cardiol 2016; 2016:4626279.
26. Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. J Clin Rheumatol 2013; 19:286–8.
27. U.S. Food and Drug Administration. EUA Chloroquine Phosphate Health Care Provider Fact Sheet April 3, 2020.
28. U.S. Food and Drug Administration. EUA Hydroxychloroquine sulfate Health Care Provider Fact Sheet March 28, 2020.
29. Chorin E, Dai M, Shulman E, et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. medRxiv 2020; 2020.04.02.20047050.
30. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2:69.
31. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395:565–74.
32. Chen J. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect 2020; 22:69–71.
33. Fantini J, Scala CD, Chahinian H, Yahi N. Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents 2020; 105960.
34. Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 2015; 70:1608–21.
35. Burkard C, Verheije MH, Wicht O, et al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog 2014; 10:e1004502.
36. Mingo RM, Simmons JA, Shoemaker CJ, et al. Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J Virol 2015; 89:2931–43.
37. Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004; 323:264–8.
38. Biot C, Daher W, Chavain N, et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem 2006; 49:2845–9.
39. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020:ciaa237.
40. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269–71.
41. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020; In Press.
42. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6:16.
43. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University 2020; In Press.
44. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 105949.
45. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020.
46. Molina JM, Delaugerre C, Goff JL, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; In Press.
47. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. Available at: https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf.
48. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14:72–3.
49. Voss A. Statement on IJAA paper. Available at: https://www.isac.world/news-andpublications/official-isac-statement. Accessed 5 April 2020.
50. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43:185–8.
51. Agencia Española de Medicamentos y Productos Sanitarios. Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2. Available at: https://www.aemps.gob.es/laAEMPS/docs/medicamentos-disponibles-SARSCoV-2-28-3-2020.pdf. Accessed 6 April 2020.
52. European Medicines Agency Science Medicines Health. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use pro-grammes. Available at: https://www.ema.europa.eu/en/documents/press-release/ covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trialsemergency-use-programmes_en.pdf. Accessed 6 April 2020.
53. Lane JWJ. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. Available at: https://data.ohdsi.org/Covid19EstimationHydroxychloroquine/. Accessed 6 April 2020.
54. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; In Press.
55. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8:420–2.
56. Lakkireddy DR, Chung MK, Gopinathannair R, et al. Guidance for cardiac electrophysiology during the coronavirus (COVID-19) pandemic from the Heart Rhythm Society COVID-19 task force; electrophysiology section of the American College of Cardiology; and the electrocardiography and arrhythmias committee of the council on clinical cardiology, American Heart Association. Heart Rhythm 2020.